Gemtesa (Vibegron) - Critical Clarification Required
Gemtesa (vibegron) is NOT indicated for metastatic castration-resistant prostate cancer (mCRPC) or any prostate cancer condition - it is exclusively approved for overactive bladder (OAB) treatment in adults. 1
Important Distinction: Gemtesa vs. Darolutamide
There appears to be confusion in your question. The evidence provided discusses darolutamide (an androgen receptor inhibitor for prostate cancer), but you asked about Gemtesa (vibegron, a beta-3 adrenergic agonist for bladder dysfunction). These are completely different medications with entirely different indications.
Gemtesa (Vibegron) - Actual Indications and Dosing
FDA-Approved Indications
- Overactive bladder in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency 1
- Overactive bladder in adult males with benign prostatic hyperplasia (BPH) who are on pharmacological therapy for BPH 1
Dosing and Administration
Standard dose: 75 mg orally once daily 1
- Take with or without food
- Swallow whole with water, OR
- May crush tablet, mix with 1 tablespoon (~15 mL) of applesauce, and take immediately with water 1
- No dose adjustments specified for renal or hepatic impairment in the label
Contraindications
Absolute contraindication: Known hypersensitivity to vibegron or any component (angioedema has occurred) 1
Critical Warnings and Monitoring
Urinary retention risk 1:
- Monitor patients with bladder outlet obstruction
- Higher risk in patients taking concurrent muscarinic antagonists for OAB
- Discontinue if urinary retention develops
Angioedema 1:
- Can occur hours after first dose or after multiple doses
- May involve face, tongue, hypopharynx, or larynx
- Immediately discontinue and ensure patent airway if upper airway involvement occurs
Common Adverse Events
From clinical trials 1:
- Urinary tract infection
- Headache
- Nasal congestion, sore throat, runny nose
- Diarrhea
- Nausea
- Upper respiratory tract infection
Drug Interactions
- Inform prescriber if patient takes digoxin (mentioned in patient counseling) 1
- No specific contraindicated combinations listed, but comprehensive medication review recommended
Special Populations
- Pregnancy/Lactation: Unknown safety; discuss risks/benefits 1
- Pediatrics: Not established as safe or effective in children 1
If You Meant Darolutamide for Prostate Cancer
If your actual question concerns darolutamide for mCRPC (not Gemtesa), the evidence shows darolutamide is primarily established for non-metastatic CRPC 2 and metastatic hormone-sensitive prostate cancer, with emerging but limited data in the mCRPC setting after prior ARTA and docetaxel exposure 3, 4, 5. Current ASCO and NCCN guidelines 6, 7 do not list darolutamide as a standard option for mCRPC, focusing instead on established ARPIs (enzalutamide, abiraterone), PARPi, chemotherapy, and radiopharmaceuticals.
Please clarify which medication you are asking about to receive the appropriate clinical guidance.